KORU Medical Systems, Inc. announced a development agreement with a pharmaceutical manufacturer of subcutaneous immunoglobulin therapy (SCIg) to develop and seek regulatory approval of the Freedom Infusion System with an SCIg prefilled syringe. The agreement provides for KORU Medical to develop an adaptation to its Freedom Infusion System to enable an SCIg prefilled syringe to be usable by patients globally and seek regulatory authorization for adaptation. Terms of the agreement were not disclosed.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.65 USD | -1.12% | +6.00% | +7.94% |
02/07 | Koru Medical Systems' FreedomEdge System Receives Regulatory Approval in Japan | MT |
02/07 | KORU Medical Systems Receives Regulatory Clearance for FreedomEdge Infusion System in Japan | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+7.94% | 121M | |
-4.90% | 182B | |
-1.36% | 104B | |
-7.64% | 45.58B | |
+9.30% | 46.44B | |
+9.63% | 44.34B | |
+13.63% | 29.44B | |
+20.29% | 26.8B | |
-7.12% | 23.82B | |
+4.03% | 22.61B |
- Stock Market
- Equities
- KRMD Stock
- News KORU Medical Systems, Inc.
- KORU Medical Systems, Inc. Announces Subcutaneous Immunoglobulin Prefilled Syringe Development Agreement